BN Business News
添加企业 →
本文翻译正在准备中。在此之前,我们暂时显示英文原文。

商业 · 2025/10/31 分钟阅读

Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications; Correction

本地自动翻译 · 来源原始语言

摘要

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on August 4, 2025 (90 FR 36440). The document announced the withdrawal of approval of 39 new drug applications (NDA) from multiple applicants, withdrawn as of September 3, 2025. The document erroneously included NDA number 021290. The correct NDA number is 020212 for Zinecard (dexrazoxane hydrochloric acid (HCl)) Injectable, equivalent to (EQ) 250 milligrams (mg) base/ vial and EQ 500 mg base/vial. This document corrects that error.

来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →

探索专题

商业洞察 →